Phase I trial of KB 003 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Lenzilumab (Primary)
- Indications Obstructive airway disorders; Rheumatic disorders
- Focus Adverse reactions
- Sponsors Humanigen; KaloBios Pharmaceuticals
- 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 05 May 2008 New trial record.
- 29 Apr 2008 Subject dosing has been completed.